With compliments:
RNS) 2006-07-12 07:03 GMT:
Sinclair Pharma PLC - Regulatory Approval
Article layout: raw
RNS Number:0613G Sinclair Pharma PLC 12 July 2006
Sinclair Pharma Plc Announces First Ophthalmology Product Approval
and Two Further Product Approvals
Godalming UK, 12 July 2006: Sinclair Pharma plc ("Sinclair" or the "Company") (SPH.L), the specialty pharmaceutical company focused on the acquisition and development of patented pharmaceutical products, today announces EU regulatory approval for a new ophthalmology product for dry eye syndrome and two new line extension products in their key therapeutic areas of oral health and dermatology.
The following products have been approved in the EU:
SPHP700 will address the prescription market for dry eye. It has been approved as a Medical Device Class I (sterile).
SPHP700 will offer a new approach to relieving the symptoms of dry eye, that are experienced by as many as 30% of the over 65s. It contains a specific polysaccharide that is able to bind large quantities of water and designed to deliver moisture to the eye surface for fast and prolonged symptom relief.
The current market leader in prescription dry eye products in the US achieves sales of $100m. Sinclair's product will be commercialized through marketing partners in key territories; licensing discussions will start in the second half of the current financial year.
RNS) 2006-07-12 07:03 GMT:
Sinclair Pharma PLC - Regulatory Approval
Article layout: raw
RNS Number:0613G Sinclair Pharma PLC 12 July 2006
Sinclair Pharma Plc Announces First Ophthalmology Product Approval
and Two Further Product Approvals
Godalming UK, 12 July 2006: Sinclair Pharma plc ("Sinclair" or the "Company") (SPH.L), the specialty pharmaceutical company focused on the acquisition and development of patented pharmaceutical products, today announces EU regulatory approval for a new ophthalmology product for dry eye syndrome and two new line extension products in their key therapeutic areas of oral health and dermatology.
The following products have been approved in the EU:
SPHP700 will address the prescription market for dry eye. It has been approved as a Medical Device Class I (sterile).
SPHP700 will offer a new approach to relieving the symptoms of dry eye, that are experienced by as many as 30% of the over 65s. It contains a specific polysaccharide that is able to bind large quantities of water and designed to deliver moisture to the eye surface for fast and prolonged symptom relief.
The current market leader in prescription dry eye products in the US achieves sales of $100m. Sinclair's product will be commercialized through marketing partners in key territories; licensing discussions will start in the second half of the current financial year.
Comment